Alpine Global Management’s Teva Pharmaceuticals TEVA Stock Holding History

Alpine Global Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-25,966	Closed	-$195K	–	496
2022 Q2	$195K	Buy	25,966 +503	+2%	+$4.38K	0.05%	124
2022 Q1	$239	Sell	25,463 -24,537	-49%	-$205K	0.05%	219
2021 Q4	$401K	Buy	+50,000	New	+$451K	0.06%	407
2021 Q2	–	Sell	-35,000	Closed	-$404K	–	368
2021 Q1	$404K	Hold	35,000	–	–	0.04%	185
2020 Q4	$338K	Hold	35,000	–	–	0.07%	116
2020 Q3	$315K	Buy	+35,000	New	+$370K	0.07%	133

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Alpine Global Management's TEVA Position: Q3 2022 in Review

Alpine Global Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2022, closing a stake of 25,966 shares — an estimated $195K sold.

Alpine Global Management first reported a position in TEVA in Q3 2020 and held it in 6 quarters. The position peaked at $404K in Q1 2021. 430 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

Alpine Global Management reported no remaining Teva Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Alpine Global Management sold 25,966 Teva Pharmaceuticals shares in Q3 2022, an estimated $195K.
Alpine Global Management first reported a position in Teva Pharmaceuticals in Q3 2020 and held it in 6 quarters.
Alpine Global Management's Teva Pharmaceuticals position peaked at $404K in Q1 2021.
430 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2022.

Based on Alpine Global Management's 13F filing for Q3 2022, filed 14 Nov 2022.